Supernus (SUPN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$830.4M

Revenue (quarter)

$219.1M

Revenue growth (year over year)

+32.40%

Gross profit (trailing twelve months)

$731.4M

Gross margin

88.07%

Net income (trailing twelve months)

−$109.9M

Net income (quarter)

−$58.4M

Net income growth (year over year)

−359.44%

Net margin

−13.23%

Return on equity

−10.49%

EPS (trailing twelve months)

−$1.92

Book value per share

$17.73

P/E (trailing twelve months)

—

Price to book

2.23

Debt to assets

27.79%

Payout ratio

—

Dividend yield

—

Company profile

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

• Is Supernus (SUPN) profitable?

  No. Supernus reported a net loss of $109.9M over the trailing twelve months.

• How much revenue does Supernus (SUPN) make?

  Supernus generated $830.4M in revenue over the trailing twelve months, up 32.40% year over year.

• How do I buy stock in Supernus (SUPN)?

  SUPN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.